Tüdőrák: vizsgálatok itt: Ausztrália
166 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleSafety and Efficacy of OBX-115 in Advanced Solid Tumors
- Where
- Wollstonecraft
- Életkor
- 18 év and over
- People
- 254 worldwide
- Run by
- Obsidian Therapeutics, Inc.
See details and how to joinNCT06060613 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Ballarat Central, Epping, Frankston, Port Macquarie, Westmead
- Életkor
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00 - 2. fázisTaking peopleA Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Where
- Camperdown, Herston, Nedlands, North Ryde, Parkville
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00 - 2. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Adelaide, Blacktown, Camperdown, Fitzroy, Hobart, Hyde Park, Kogarah, Murdoch, Nedlands, Saint Leonards
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - 1. fázisTaking peopleStudy of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Where
- Darlinghurst
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07660055 - Korai 1. fázisTaking people177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- Where
- Adelaide, Gosford, Kingswood, Murdoch, Southport, Wollongong
- Életkor
- 18 év and over
- People
- 30
- Run by
- Radiopharm Theranostics, Ltd
See details and how to joinNCT06305962 - 2/3. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Adelaide, Bedford Park, Cairns, Dubbo, Frankston, Joondalup, Kurralta Park, Melbourne, Orange, Southport, St Albans, Townsville, Wollongong
- Életkor
- 18 év and over
- People
- 1580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - 3. fázisTaking peopleStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Where
- Blacktown, Camperdown, Heidelberg, St Leonards
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07185997 - 3. fázisTaking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Bedford Park, Heidelberg, Subiaco, Sydney, Woolloongabba
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - 3. fázisTaking peopleEvaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
- Where
- Fitzroy
- Életkor
- 18 év and over
- People
- 132 worldwide
- Run by
- Vergent Bioscience, Inc.
See details and how to joinNCT07499674 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Ballarat, Bedford Park, Clayton, Garran, Hyde Park, Port Macquarie, Wollongong, Woolloongabba
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1/2. fázisTaking peopleFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Camperdown
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Geelong, Heidelberg, Port Macquarie, Westmead
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Darlinghurst, Hyde Park, Southport, Wollongong
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 2. fázisTaking peopleDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Adelaide, Benowa, Birtinya, North Sydney
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 1. fázisTaking peopleA Study of MGC026 in Participants With Advanced Solid Tumors
- Where
- Auchenflower, Heidelberg, Kurralta Park
- Életkor
- 18 év and over
- People
- 394 worldwide
- Run by
- MacroGenics
See details and how to joinNCT06242470 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Birtinya, Blacktown, Clayton, Gosford, Melbourne, South Brisbane, Wodonga
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Darlinghurst, Hyde Park, Southport, Wollongong
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 1/2. fázisTaking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Blacktown, Elizabeth Vale, Frankston, Townsville
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - 1/2. fázisTaking peoplePhase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Where
- Wollstonecraft
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Strand Therapeutics Inc.
See details and how to joinNCT07751042 - 2/3. fázisTaking peopleGlobal, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Where
- Coffs Harbour, Melbourne, Newcastle, Sydney
- Életkor
- 18 év to 80 év
- People
- 512 worldwide
- Run by
- Multitude Therapeutics Inc.
See details and how to joinNCT07718737 - 1. fázisNot yet taking people in AusztráliaA Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- Where
- Blacktown, Camperdown
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT06905197 - 3. fázisTaking peoplePrimary Radiotherapy In MEtastatic Lung Cancer
- Where
- Adelaide, Ballarat, Blacktown, Gold Coast, Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 420
- Run by
- Trans Tasman Radiation Oncology Group
See details and how to joinNCT07135882 - 3. fázisTaking peopleA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Ballarat Central, Elizabeth Vale, Epping, Gosford, Joondalup, Penrith
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00 - 2. fázisTaking peopleA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Gosford, Greenslopes, Heidelberg, Perth, Westmead
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00